{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:43:45Z","timestamp":1793598225634,"version":"4.5.0"},"reference-count":207,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T00:00:00Z","timestamp":1364256000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1038\/nrclinonc.2013.41","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T08:44:14Z","timestamp":1364287454000},"page":"289-301","source":"Crossref","is-referenced-by-count":230,"title":["Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors"],"prefix":"10.1038","volume":"10","author":[{"given":"Lois B.","family":"Travis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy Demark","family":"Wahnefried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie E.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea K.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,26]]},"reference":[{"key":"BFnrclinonc201341_CR1","unstructured":"National Cancer Institute. SEER Cancer Statistics Review, 1975\u20132007 [online] , (2010)."},{"key":"BFnrclinonc201341_CR2","unstructured":"National Cancer Institute. Provocative questions: identifying problems to drive progress against cancer [online] , (2012)."},{"key":"BFnrclinonc201341_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3322\/caac.21149","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel, R. et al. Cancer treatment and survivorship statistics. CA Cancer J. Clin. 62, 220\u2013241 (2012).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrclinonc201341_CR4","doi-asserted-by":"crossref","unstructured":"[No authors listed]. Cancer survivors: living longer, and now, better. Lancet 364, 2153\u20132154 (2004).","DOI":"10.1016\/S0140-6736(04)17601-0"},{"key":"BFnrclinonc201341_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/028418602760169361","volume":"41","author":"LB Travis","year":"2002","unstructured":"Travis, L. B. Therapy-associated solid tumors. Acta Oncol. 41, 323\u2013333 (2002).","journal-title":"Acta Oncol."},{"key":"BFnrclinonc201341_CR6","first-page":"181","volume-title":"New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973\u20132000","author":"RE Curtis","year":"2006","unstructured":"Curtis, R. E., Ron, E., Hankey, B. F. & Hoover, R. N. in New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973\u20132000 (eds Curtis, R. E. et al.) NIH Publ. No. 05\u20130532, 181\u2013206 (National Cancer Institute, 2006)."},{"key":"BFnrclinonc201341_CR7","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1200\/JCO.2002.08.021","volume":"20","author":"AK Ng","year":"2002","unstructured":"Ng, A. K. et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J. Clin. Oncol. 20, 2101\u20132108 (2002).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/jnci\/djj001","volume":"98","author":"LB Travis","year":"2006","unstructured":"Travis, L. B. et al. Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J. Natl Cancer Inst. 98, 15\u201325 (2006).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR9","first-page":"2393","volume-title":"Cancer: Principles and Practice of Oncology","author":"LB Travis","year":"2011","unstructured":"Travis, L. B., Bhatia, S., Allan, J. M., Oeffinger, K. C. & Ng, A. in Cancer: Principles and Practice of Oncology, 9th edn (eds Devita, V. T., Lawrence, T. S. & Rosenberg, S. A.) 2393\u20132410 (Lippincott Williams and Wilkins, 2011)."},{"key":"BFnrclinonc201341_CR10","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1200\/JCO.2002.09.038","volume":"20","author":"GM Dores","year":"2002","unstructured":"Dores, G. M. et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J. Clin. Oncol. 20, 3484\u20133494 (2002).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR11","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1093\/annonc\/mdl302","volume":"17","author":"J Franklin","year":"2006","unstructured":"Franklin, J. et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann. Oncol. 17, 1749\u20131760 (2006).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc201341_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1365-2141.2012.09211.x","volume":"158","author":"B Omer","year":"2012","unstructured":"Omer, B. et al. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. Br. J. Haematol. 158, 615\u2013625 (2012).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc201341_CR13","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","volume":"25","author":"DC Hodgson","year":"2007","unstructured":"Hodgson, D. C. et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J. Clin. Oncol. 25, 1489\u20131497 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR14","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/annonc\/mdp562","volume":"21","author":"K Hemminki","year":"2010","unstructured":"Hemminki, K., Liu, H. & Sundquist, J. Second cancers after testicular cancer diagnosed after in Sweden. Ann. Oncol. 21, 1546\u20131551 (2010) (1980).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc201341_CR15","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/jnci\/dji278","volume":"97","author":"LB Travis","year":"2005","unstructured":"Travis, L. B. et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J. Natl Cancer Inst. 97, 1354\u20131365 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR16","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1200\/JCO.2006.10.5296","volume":"25","author":"AW van den Belt-Dusebout","year":"2007","unstructured":"van den Belt-Dusebout, A. W. et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol. 25, 4370\u20134378 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/jnci\/djr533","volume":"104","author":"LB Travis","year":"2012","unstructured":"Travis, L. B. et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. J. Natl Cancer Inst. 104, 357\u2013370 (2012).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR18","unstructured":"National Council on Radiation Protection and Measurements. Report No. 170: Second Primary Cancers and Cardiovascular Disease After Radiotherapy [online] , (2012)."},{"key":"BFnrclinonc201341_CR19","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/jnci\/djm201","volume":"99","author":"AK Chaturvedi","year":"2007","unstructured":"Chaturvedi, A. K. et al. Second cancers among 104, 760 survivors of cervical cancer: evaluation of long-term risk. J. Natl Cancer Inst. 99, 1634\u20131643 (2007).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ijrobp.2009.02.011","volume":"76","author":"N Bhojani","year":"2010","unstructured":"Bhojani, N. et al. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int. J. Radiat. Oncol. Biol. Phys. 76, 342\u2013348 (2010).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrclinonc201341_CR21","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/ijc.23601","volume":"123","author":"E Rapiti","year":"2008","unstructured":"Rapiti, E. et al. Increased risk of colon cancer after external radiation therapy for prostate cancer. Int. J. Cancer 123, 1141\u20131145 (2008).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201341_CR22","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/cncr.21223","volume":"104","author":"YM Kirova","year":"2005","unstructured":"Kirova, Y. M., Vilcoq, J. R., Asselain, B., Sastre-Garau, X. & Fourquet, A. Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. Cancer 104, 856\u2013863 (2005).","journal-title":"Cancer"},{"key":"BFnrclinonc201341_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2325\/jbcs.914","volume":"14","author":"R Nakamura","year":"2007","unstructured":"Nakamura, R. et al. Angiosarcoma arising in the breast following breast-conserving surgery with radiation for breast carcinoma. Breast Cancer 14, 245\u2013249 (2007).","journal-title":"Breast Cancer"},{"key":"BFnrclinonc201341_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10549-004-2472-8","volume":"89","author":"C Rubino","year":"2005","unstructured":"Rubino, C. et al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res. Treat. 89, 277\u2013288 (2005).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrclinonc201341_CR25","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2007.13.3033","volume":"26","author":"EL Kaufman","year":"2008","unstructured":"Kaufman, E. L., Jacobson, J. S., Hershman, D. L., Desai, M. & Neugut, A. I. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J. Clin. Oncol. 26, 392\u2013398 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR26","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1002\/1097-0142(19930515)71:10<3054::AID-CNCR2820711027>3.0.CO;2-N","volume":"71","author":"AI Neugut","year":"1993","unstructured":"Neugut, A. I. et al. Lung cancer after radiation therapy for breast cancer. Cancer 71, 3054\u20133057 (1993).","journal-title":"Cancer"},{"key":"BFnrclinonc201341_CR27","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/aje\/kwi050","volume":"161","author":"LB Zablotska","year":"2005","unstructured":"Zablotska, L. B., Chak, A., Das, A. & Neugut, A. I. Increased risk of squamous cell esophageal cancer after adjuvant radiation therapy for primary breast cancer. Am. J. Epidemiol. 161, 330\u2013337 (2005).","journal-title":"Am. J. Epidemiol."},{"key":"BFnrclinonc201341_CR28","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJM199203193261201","volume":"326","author":"JD Boice Jr","year":"1992","unstructured":"Boice, J. D. Jr, Harvey, E. B., Blettner, M., Stovall, M. & Flannery, J. T. Cancer in the contralateral breast after radiotherapy for breast cancer. N. Engl. J. Med. 326, 781\u2013785 (1992).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201341_CR29","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1200\/JCO.2007.16.0192","volume":"26","author":"MJ Hooning","year":"2008","unstructured":"Hooning, M. J. et al. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J. Clin. Oncol. 26, 5561\u20135568 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR30","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.ijrobp.2008.02.040","volume":"72","author":"M Stovall","year":"2008","unstructured":"Stovall, M. et al. Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. Int. J. Radiat. Oncol. Biol. Phys. 72, 1021\u20131030 (2008).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrclinonc201341_CR31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1470-2045(11)70061-4","volume":"12","author":"A Berrington de Gonzalez","year":"2011","unstructured":"Berrington de Gonzalez, A. et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 12, 353\u2013360 (2011).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201341_CR32","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1000067","volume":"363","author":"A Engert","year":"2010","unstructured":"Engert, A. et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N. Engl. J. Med. 363, 640\u2013652 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201341_CR33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","volume":"79","author":"T Girinsky","year":"2006","unstructured":"Girinsky, T. et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother. Oncol. 79, 270\u2013277 (2006).","journal-title":"Radiother. Oncol."},{"key":"BFnrclinonc201341_CR34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0360-3016(98)90034-7","volume":"15","author":"JR Harris","year":"1988","unstructured":"Harris, J. R. & Hellman, S. Put the \u201chockey stick\u201d on ice. Int. J. Radiat. Oncol. Biol. Phys. 15, 497\u2013499 (1988).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrclinonc201341_CR35","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO.2003.06.065","volume":"21","author":"J Classen","year":"2003","unstructured":"Classen, J. et al. Radiotherapy for stages IIA\/B testicular seminoma: final report of a prospective multicenter clinical trial. J. Clin. Oncol. 21, 1101\u20131106 (2003).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR36","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1038\/sj.bjc.6601867","volume":"90","author":"J Classen","year":"2004","unstructured":"Classen, J. et al. Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br. J. Cancer 90, 2305\u20132311 (2004).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc201341_CR37","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1001\/jama.1997.03550150066037","volume":"278","author":"FL Wong","year":"1997","unstructured":"Wong, F. L. et al. Cancer incidence after retinoblastoma. radiation dose and sarcoma risk. JAMA 278, 1262\u20131267 (1997).","journal-title":"JAMA"},{"key":"BFnrclinonc201341_CR38","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1200\/JCO.1996.14.10.2818","volume":"14","author":"JF Kuttesch Jr","year":"1996","unstructured":"Kuttesch, J. F. Jr et al. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J. Clin. Oncol. 14, 2818\u20132825 (1996).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jama.290.4.465","volume":"290","author":"LB Travis","year":"2003","unstructured":"Travis, L. B. et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290, 465\u2013475 (2003).","journal-title":"JAMA"},{"key":"BFnrclinonc201341_CR40","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","volume":"94","author":"LB Travis","year":"2002","unstructured":"Travis, L. B. et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J. Natl Cancer Inst. 94, 182\u2013192 (2002).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR41","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.ijrobp.2009.01.073","volume":"75","author":"AW van den Belt-Dusebout","year":"2009","unstructured":"van den Belt-Dusebout, A. W. et al. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int. J. Radiat. Oncol. Biol. Phys. 75, 1420\u20131429 (2009).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrclinonc201341_CR42","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1093\/jnci\/djj411","volume":"98","author":"JP Neglia","year":"2006","unstructured":"Neglia, J. P. et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J. Natl Cancer Inst. 98, 1528\u20131537 (2006).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR43","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1667\/RR2240.1","volume":"174","author":"P Bhatti","year":"2010","unstructured":"Bhatti, P. et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the Childhood Cancer Survivor Study. Radiat. Res. 174, 741\u2013752 (2010).","journal-title":"Radiat. Res."},{"key":"BFnrclinonc201341_CR44","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1016\/S0140-6736(05)66695-0","volume":"365","author":"AJ Sigurdson","year":"2005","unstructured":"Sigurdson, A. J. et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet 365, 2014\u20132023 (2005).","journal-title":"Lancet"},{"key":"BFnrclinonc201341_CR45","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1200\/JCO.2008.19.9174","volume":"27","author":"ML De Bruin","year":"2009","unstructured":"De Bruin, M. L. et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J. Clin. Oncol. 27, 4239\u20134246 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR46","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","volume":"100","author":"AK Ng","year":"2002","unstructured":"Ng, A. K. et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 100, 1989\u20131996 (2002).","journal-title":"Blood"},{"key":"BFnrclinonc201341_CR47","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.ijrobp.2005.03.053","volume":"62","author":"SF Kry","year":"2005","unstructured":"Kry, S. F. et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 62, 1195\u20131203 (2005).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrclinonc201341_CR48","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/01.HP.0000326342.47348.06","volume":"95","author":"JA Purdy","year":"2008","unstructured":"Purdy, J. A. Dose to normal tissues outside the radiation therapy patient's treated volume: a review of different radiation therapy techniques. Health Phys. 95, 666\u2013676 (2008).","journal-title":"Health Phys."},{"key":"BFnrclinonc201341_CR49","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3109\/0284186X.2011.582514","volume":"50","author":"NP Brodin","year":"2011","unstructured":"Brodin, N. P. et al. Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. Acta Oncol. 50, 806\u2013816 (2011).","journal-title":"Acta Oncol."},{"key":"BFnrclinonc201341_CR50","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1118\/1.3367012","volume":"37","author":"B Bednarz","year":"2010","unstructured":"Bednarz, B., Athar, B. & Xu, X. G. A comparative study on the risk of second primary cancers in out-of-field organs associated with radiotherapy of localized prostate carcinoma using Monte Carlo-based accelerator and patient models. Medical Phys. 37, 1987\u20131994 (2010).","journal-title":"Medical Phys."},{"key":"BFnrclinonc201341_CR51","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ijrobp.2009.01.051","volume":"74","author":"DR Zwahlen","year":"2009","unstructured":"Zwahlen, D. R. et al. Effect of intensity-modulated pelvic radiotherapy on second cancer risk in the postoperative treatment of endometrial and cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 74, 539\u2013545 (2009).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrclinonc201341_CR52","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ijrobp.2008.04.069","volume":"72","author":"C Zacharatou Jarlskog","year":"2008","unstructured":"Zacharatou Jarlskog, C. & Paganetti, H. Risk of developing second cancer from neutron dose in proton therapy as function of field characteristics, organ, and patient age. Int. J. Radiat. Oncol. Biol. Phys. 72, 228\u2013235 (2008).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrclinonc201341_CR53","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"S Swerdlow","year":"2008","unstructured":"Swerdlow, S. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn (IARC Press, 2008)."},{"key":"BFnrclinonc201341_CR54","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/j.1476-5381.2010.01100.x","volume":"162","author":"H Sill","year":"2011","unstructured":"Sill, H., Olipitz, W., Zebisch, A., Schulz, E. & Wolfler, A. Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Br. J. Pharmacol. 162, 792\u2013805 (2011).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrclinonc201341_CR55","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal, M. et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1782\u20131791 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201341_CR56","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy, P. L. et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1770\u20131781 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201341_CR57","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1182\/blood.V86.9.3542.bloodjournal8693542","volume":"86","author":"J Pedersen-Bjergaard","year":"1995","unstructured":"Pedersen-Bjergaard, J., Pedersen, M., Roulston, D. & Philip, P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 86, 3542\u20133552 (1995).","journal-title":"Blood"},{"key":"BFnrclinonc201341_CR58","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3324\/haematol.11034","volume":"92","author":"G Leone","year":"2007","unstructured":"Leone, G., Pagano, L., Ben-Yehuda, D. & Voso, M. T. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 92, 1389\u20131398 (2007).","journal-title":"Haematologica"},{"key":"BFnrclinonc201341_CR59","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJM199902043400504","volume":"340","author":"LB Travis","year":"1999","unstructured":"Travis, L. B. et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N. Engl. J. Med. 340, 351\u2013357 (1999).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201341_CR60","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/jnci\/92.14.1165","volume":"92","author":"LB Travis","year":"2000","unstructured":"Travis, L. B. et al. Treatment-associated leukemia following testicular cancer. J. Natl Cancer Inst. 92, 1165\u20131171 (2000).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR61","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0140-6736(91)90490-G","volume":"338","author":"J Pedersen-Bjergaard","year":"1991","unstructured":"Pedersen-Bjergaard, J. et al. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 338, 359\u2013363 (1991).","journal-title":"Lancet"},{"key":"BFnrclinonc201341_CR62","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1365-2141.2007.06613.x","volume":"137","author":"C Seedhouse","year":"2007","unstructured":"Seedhouse, C. & Russell, N. Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia. Br. J. Haematol. 137, 513\u2013529 (2007).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc201341_CR63","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1053\/j.seminoncol.2008.04.012","volume":"35","author":"LA Godley","year":"2008","unstructured":"Godley, L. A. & Larson, R. A. Therapy-related myeloid leukemia. Semin. Oncol. 35, 418\u2013429 (2008).","journal-title":"Semin. Oncol."},{"key":"BFnrclinonc201341_CR64","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1200\/JCO.2007.15.1530","volume":"27","author":"X Leleu","year":"2009","unstructured":"Leleu, X. et al. Increased incidence of transformation and myelodysplasia\/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J. Clin. Oncol. 27, 250\u2013255 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR65","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1200\/JCO.2002.08.128","volume":"20","author":"VA Morrison","year":"2002","unstructured":"Morrison, V. A. et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an Intergroup Study, Cancer and Leukemia Group B 9011. J. Clin. Oncol. 20, 3878\u20133884 (2002).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR66","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jama.1990.03450080092038","volume":"264","author":"AI Neugut","year":"1990","unstructured":"Neugut, A. I., Robinson, E., Nieves, J., Murray, T. & Tsai, W. Y. Poor survival of treatment-related acute nonlymphocytic leukemia. JAMA 264, 1006\u20131008 (1990).","journal-title":"JAMA"},{"key":"BFnrclinonc201341_CR67","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1038\/sj.leu.2402713","volume":"16","author":"N Mauritzson","year":"2002","unstructured":"Mauritzson, N. et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976\u20131993 and on 5098 unselected cases reported in the literature 1974\u20132001. Leukemia 16, 2366\u20132378 (2002).","journal-title":"Leukemia"},{"key":"BFnrclinonc201341_CR68","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/sj.leu.2403187","volume":"18","author":"C Schoch","year":"2004","unstructured":"Schoch, C., Kern, W., Schnittger, S., Hiddemann, W. & Haferlach, T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 18, 120\u2013125 (2004).","journal-title":"Leukemia"},{"key":"BFnrclinonc201341_CR69","doi-asserted-by":"publisher","first-page":"945","DOI":"10.6004\/jnccn.2011.0077","volume":"9","author":"GH Lyman","year":"2011","unstructured":"Lyman, G. H. & Dale, D. C. Long-term outcomes of myeloid growth factor treatment. J. Natl Compr. Canc. Netw. 9, 945\u2013952 (2011).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"BFnrclinonc201341_CR70","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/jnci\/djk028","volume":"99","author":"D Hershman","year":"2007","unstructured":"Hershman, D. et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J. Natl Cancer Inst. 99, 196\u2013205 (2007).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR71","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1200\/JCO.2009.25.8723","volume":"28","author":"GH Lyman","year":"2010","unstructured":"Lyman, G. H. et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J. Clin. Oncol. 28, 2914\u20132924 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR72","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ijrobp.2011.11.022","volume":"84","author":"TO Henderson","year":"2012","unstructured":"Henderson, T. O. et al. Risk factors associated with secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study. Int. J. Radiat. Oncol. Biol. Phys. 84, 224\u2013230 (2012).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrclinonc201341_CR73","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1200\/JCO.2001.19.6.1610","volume":"19","author":"AJ Swerdlow","year":"2001","unstructured":"Swerdlow, A. J. et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J. Clin. Oncol. 19, 1610\u20131618 (2001).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR74","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/jnci\/87.20.1530","volume":"87","author":"FE van Leeuwen","year":"1995","unstructured":"van Leeuwen, F. E. et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J. Natl Cancer Inst. 87, 1530\u20131537 (1995).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR75","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1200\/JCO.2011.34.8268","volume":"29","author":"AJ Swerdlow","year":"2011","unstructured":"Swerdlow, A. J. et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J. Clin. Oncol. 29, 4096\u20134104 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR76","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1182\/blood-2003-04-1124","volume":"103","author":"M Andre","year":"2004","unstructured":"Andre, M. et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood 103, 1222\u20131228 (2004).","journal-title":"Blood"},{"key":"BFnrclinonc201341_CR77","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1200\/JCO.2005.04.2200","volume":"24","author":"NY Mudie","year":"2006","unstructured":"Mudie, N. Y. et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British cohort study. J. Clin. Oncol. 24, 1568\u20131574 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR78","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1200\/JCO.2011.37.8760","volume":"30","author":"K Nottage","year":"2012","unstructured":"Nottage, K. et al. Secondary colorectal carcinoma after childhood cancer. J. Clin. Oncol. 30, 2552\u20132558 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR79","doi-asserted-by":"publisher","first-page":"757","DOI":"10.7326\/0003-4819-156-11-201206050-00002","volume":"156","author":"TO Henderson","year":"2012","unstructured":"Henderson, T. O. et al. Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann. Intern. Med. 156, 757\u2013766 (2012).","journal-title":"Ann. Intern. Med."},{"key":"BFnrclinonc201341_CR80","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","volume":"87","author":"LB Travis","year":"1995","unstructured":"Travis, L. B. et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J. Natl Cancer Inst. 87, 524\u2013530 (1995).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR81","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/sj.bjc.6605325","volume":"101","author":"JL Bermejo","year":"2009","unstructured":"Bermejo, J. L., Sundquist, J. & Hemminki, K. Bladder cancer in cancer patients: population-based estimates from a large Swedish study. Br. J. Cancer 101, 1091\u20131099 (2009).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc201341_CR82","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1158\/1055-9965.EPI-11-0576","volume":"21","author":"LH Veiga","year":"2012","unstructured":"Veiga, L. H. et al. Chemotherapy and thyroid cancer risk: a report from the childhood cancer survivor study. Cancer Epidemiol. Biomarkers Prev. 21, 92\u2013101 (2012).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"BFnrclinonc201341_CR83","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG) et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771\u2013784 (2011).","DOI":"10.1016\/S0140-6736(11)60993-8"},{"key":"BFnrclinonc201341_CR84","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90, 1371\u20131388 (1998).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR85","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick, J. et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11, 1135\u20131141 (2010).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201341_CR86","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","volume":"28","author":"HJ Burstein","year":"2010","unstructured":"Burstein, H. J. et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 28, 3784\u20133796 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR87","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1056\/NEJM198909213211203","volume":"321","author":"RP Witherspoon","year":"1989","unstructured":"Witherspoon, R. P. et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N. Engl. J. Med. 321, 784\u2013789 (1989).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201341_CR88","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1046\/j.1365-2141.1999.01627.x","volume":"106","author":"DW Milligan","year":"1999","unstructured":"Milligan, D. W. et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br. J. Haematol. 106, 1020\u20131026 (1999).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc201341_CR89","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1200\/JCO.2005.05.158","volume":"23","author":"JR Brown","year":"2005","unstructured":"Brown, J. R. et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J. Clin. Oncol. 23, 2208\u20132214 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR90","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1182\/blood.V87.9.3633.bloodjournal8793633","volume":"87","author":"S Bhatia","year":"1996","unstructured":"Bhatia, S. et al. Malignant neoplasms following bone marrow transplantation. Blood 87, 3633\u20133639 (1996).","journal-title":"Blood"},{"key":"BFnrclinonc201341_CR91","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2008-05-158782","volume":"113","author":"JD Rizzo","year":"2009","unstructured":"Rizzo, J. D. et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113, 1175\u20131183 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201341_CR92","first-page":"2208","volume":"94","author":"RE Curtis","year":"1999","unstructured":"Curtis, R. E. et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94, 2208\u20132216 (1999).","journal-title":"Blood"},{"key":"BFnrclinonc201341_CR93","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1056\/NEJM199703273361301","volume":"336","author":"RE Curtis","year":"1997","unstructured":"Curtis, R. E. et al. Solid cancers after bone marrow transplantation. N. Engl. J. Med. 336, 897\u2013904 (1997).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201341_CR94","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1182\/blood.V95.5.1588.005k38_1588_1593","volume":"95","author":"A Krishnan","year":"2000","unstructured":"Krishnan, A. et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 95, 1588\u20131593 (2000).","journal-title":"Blood"},{"issue":"Suppl.","key":"BFnrclinonc201341_CR95","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1016\/j.bbmt.2011.10.005","volume":"18","author":"G Socie","year":"2012","unstructured":"Socie, G., Baker, K. S. & Bhatia, S. Subsequent malignant neoplasms after hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 18 (Suppl.), S139\u2013S150 (2012).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"BFnrclinonc201341_CR96","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1182\/blood-2008-09-178046","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren, O. et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 113, 4992\u20135001 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201341_CR97","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s11864-011-0177-x","volume":"13","author":"D Jagadeesh","year":"2012","unstructured":"Jagadeesh, D., Woda, B. A., Draper, J. & Evens, A. M. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr. Treat. Options Oncol. 13, 122\u2013136 (2012).","journal-title":"Curr. Treat. Options Oncol."},{"key":"BFnrclinonc201341_CR98","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1182\/blood-2007-07-099283","volume":"111","author":"DL Friedman","year":"2008","unstructured":"Friedman, D. L. et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood 111, 939\u2013944 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc201341_CR99","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1200\/JCO.2001.19.2.464","volume":"19","author":"S Bhatia","year":"2001","unstructured":"Bhatia, S. et al. Solid cancers after bone marrow transplantation. J. Clin. Oncol. 19, 464\u2013471 (2001).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR100","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/cncr.22375","volume":"109","author":"G Gallagher","year":"2007","unstructured":"Gallagher, G. & Forrest, D. L. Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer 109, 84\u201392 (2007).","journal-title":"Cancer"},{"key":"BFnrclinonc201341_CR101","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1182\/blood-2010-07-294629","volume":"117","author":"NS Majhail","year":"2011","unstructured":"Majhail, N. S. et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 117, 316\u2013322 (2011).","journal-title":"Blood"},{"key":"BFnrclinonc201341_CR102","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1200\/JCO.2005.02.7052","volume":"24","author":"W Leisenring","year":"2006","unstructured":"Leisenring, W., Friedman, D. L., Flowers, M. E., Schwartz, J. L. & Deeg, H. J. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J. Clin. Oncol. 24, 1119\u20131126 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR103","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MC King","year":"2003","unstructured":"King, M. C., Marks, J. H., Mandell, J. B. & New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302, 643\u2013646 (2003).","journal-title":"Science"},{"key":"BFnrclinonc201341_CR104","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1053\/j.gastro.2009.07.039","volume":"137","author":"E Stoffel","year":"2009","unstructured":"Stoffel, E. et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 137, 1621\u20131627 (2009).","journal-title":"Gastroenterology"},{"key":"BFnrclinonc201341_CR105","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1001\/jama.2011.743","volume":"305","author":"V Bonadona","year":"2011","unstructured":"Bonadona, V. et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305, 2304\u20132310 (2011).","journal-title":"JAMA"},{"key":"BFnrclinonc201341_CR106","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ygyno.2004.09.039","volume":"96","author":"KA Metcalfe","year":"2005","unstructured":"Metcalfe, K. A. et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol. Oncol. 96, 222\u2013226 (2005).","journal-title":"Gynecol. Oncol."},{"key":"BFnrclinonc201341_CR107","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/annonc\/mdg028","volume":"14","author":"F Levi","year":"2003","unstructured":"Levi, F., Te, V. C., Randimbison, L. & La Vecchia, C. Cancer risk in women with previous breast cancer. Ann. Oncol. 14, 71\u201373 (2003).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc201341_CR108","doi-asserted-by":"publisher","first-page":"R156","DOI":"10.1186\/bcr3369","volume":"14","author":"K Rhiem","year":"2012","unstructured":"Rhiem, K. et al. The risk of contralateral breast cancer in patients from BRCA1\/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res. 14, R156 (2012).","journal-title":"Breast Cancer Res."},{"key":"BFnrclinonc201341_CR109","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.2012.43.2013","volume":"31","author":"AS Reiner","year":"2013","unstructured":"Reiner, A. S. et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the women's environmental cancer and radiation epidemiology study. J. Clin. Oncol. 31, 433\u2013439 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR110","doi-asserted-by":"publisher","unstructured":"Domchek, S. M. et al. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer http:\/\/dx.doi.org\/10.1002\/cncr.27842 .","DOI":"10.1002\/cncr.27842"},{"key":"BFnrclinonc201341_CR111","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/jnci\/djs351","volume":"104","author":"AK Win","year":"2012","unstructured":"Win, A. K. et al. Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. J. Natl Cancer Inst. 104, 1363\u20131372 (2012).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR112","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1136\/gut.2010.228056","volume":"60","author":"S Parry","year":"2011","unstructured":"Parry, S. et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 60, 950\u2013957 (2011).","journal-title":"Gut"},{"key":"BFnrclinonc201341_CR113","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1158\/1541-7786.MCR-08-0020","volume":"6","author":"MB Kastan","year":"2008","unstructured":"Kastan, M. B. DNA damage responses: mechanisms and roles in human disease: 2007 G. H. A. Clowes Memorial Award Lecture. Mol. Cancer Res. 6, 517\u2013524 (2008).","journal-title":"Mol. Cancer Res."},{"key":"BFnrclinonc201341_CR114","first-page":"300","volume":"12","author":"C Nutting","year":"2000","unstructured":"Nutting, C. et al. A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? Clin. Oncol. (R. Coll. Radiol) 12, 300\u2013304 (2000).","journal-title":"Clin. Oncol. (R. Coll. Radiol)"},{"key":"BFnrclinonc201341_CR115","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ijc.1021","volume":"96","author":"JM Limacher","year":"2001","unstructured":"Limacher, J. M., Frebourg, T., Natarajan-Ame, S. & Bergerat, J. P. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int. J. Cancer 96, 238\u2013242 (2001).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201341_CR116","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1038\/sj.onc.1204621","volume":"20","author":"JM Birch","year":"2001","unstructured":"Birch, J. M. et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20, 4621\u20134628 (2001).","journal-title":"Oncogene"},{"key":"BFnrclinonc201341_CR117","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.5858\/2009-0015-OA.1","volume":"134","author":"SS Talwalkar","year":"2010","unstructured":"Talwalkar, S. S. et al. Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome. Arch. Pathol. Lab. Med. 134, 1010\u20131015 (2010).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"BFnrclinonc201341_CR118","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1001\/jama.2011.473","volume":"305","author":"DC Link","year":"2011","unstructured":"Link, D. C. et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA 305, 1568\u20131576 (2011).","journal-title":"JAMA"},{"key":"BFnrclinonc201341_CR119","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1200\/JCO.2005.05.054","volume":"23","author":"RA Kleinerman","year":"2005","unstructured":"Kleinerman, R. A. et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J. Clin. Oncol. 23, 2272\u20132279 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR120","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/bjc.1986.110","volume":"53","author":"GJ Draper","year":"1986","unstructured":"Draper, G. J., Sanders, B. M. & Kingston, J. E. Second primary neoplasms in patients with retinoblastoma. Br. J. Cancer 53, 661\u2013671 (1986).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc201341_CR121","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1200\/JCO.2005.03.8349","volume":"24","author":"S Sharif","year":"2006","unstructured":"Sharif, S. et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J. Clin. Oncol. 24, 2570\u20132575 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR122","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/bjc.1991.435","volume":"64","author":"DG Evans","year":"1991","unstructured":"Evans, D. G., Farndon, P. A., Burnell, L. D., Gattamaneni, H. R. & Birch, J. M. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br. J. Cancer 64, 959\u2013961 (1991).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc201341_CR123","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1023\/A:1018464328836","volume":"8","author":"AM Goldstein","year":"1997","unstructured":"Goldstein, A. M., Yuen, J. & Tucker, M. A. Second cancers after medulloblastoma: population-based results from the United States and Sweden. Cancer Causes Control 8, 865\u2013871 (1997).","journal-title":"Cancer Causes Control"},{"key":"BFnrclinonc201341_CR124","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/ijc.25067","volume":"127","author":"NE Breslow","year":"2010","unstructured":"Breslow, N. E. et al. Secondary malignant neoplasms after Wilms tumor: an international collaborative study. Int. J. Cancer 127, 657\u2013666 (2010).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201341_CR125","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/jnci\/djq055","volume":"102","author":"JL Bernstein","year":"2010","unstructured":"Bernstein, J. L. et al. Radiation exposure, the ATM gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J. Natl Cancer Inst. 102, 475\u2013483 (2010).","journal-title":"J. Natl Cancer Inst."},{"issue":"Suppl. 1","key":"BFnrclinonc201341_CR126","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1007\/s00247-008-1015-6","volume":"39","author":"RA Kleinerman","year":"2009","unstructured":"Kleinerman, R. A. Radiation-sensitive genetically susceptible pediatric sub-populations. Pediatr. Radiol. 39 (Suppl. 1), S27\u2013S31 (2009).","journal-title":"Pediatr. Radiol."},{"key":"BFnrclinonc201341_CR127","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/01.HP.0000326339.06405.ea","volume":"95","author":"JM Allan","year":"2008","unstructured":"Allan, J. M. Genetic susceptibility to radiogenic cancer in humans. Health Phys. 95, 677\u2013686 (2008).","journal-title":"Health Phys."},{"key":"BFnrclinonc201341_CR128","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/ng853","volume":"31","author":"PD Pharoah","year":"2002","unstructured":"Pharoah, P. D. et al. Polygenic susceptibility to breast cancer and implications for prevention. Nat. Genet. 31, 33\u201336 (2002).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201341_CR129","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S1535-6108(02)00079-X","volume":"1","author":"J Peto","year":"2002","unstructured":"Peto, J. Breast cancer susceptibility-a new look at an old model. Cancer Cell 1, 411\u2013412 (2002).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc201341_CR130","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1055-9965.EPI-06-0270","volume":"15","author":"M Berwick","year":"2006","unstructured":"Berwick, M. et al. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol. Biomarkers Prev. 15, 1520\u20131525 (2006).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"BFnrclinonc201341_CR131","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1038\/jid.2011.235","volume":"131","author":"M Berwick","year":"2011","unstructured":"Berwick, M. et al. Interaction of CDKN2A and sun exposure in the etiology of melanoma in the general population. J. Invest. Dermatol. 131, 2500\u20132503 (2011).","journal-title":"J. Invest. Dermatol."},{"key":"BFnrclinonc201341_CR132","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/jnci\/94.12.894","volume":"9","author":"DT Bishop","year":"2002","unstructured":"Bishop, D. T. et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J. Natl Cancer Inst. 9, 894\u2013903 (2002).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR133","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/ng.219","volume":"40","author":"MC Di Bernardo","year":"2008","unstructured":"Di Bernardo, M. C. et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat. Genet. 40, 1204\u20131210 (2008).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201341_CR134","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1365-2141.2009.07946.x","volume":"148","author":"P Broderick","year":"2010","unstructured":"Broderick, P. et al. IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma. Br. J. Haematol. 148, 413\u2013415 (2010).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc201341_CR135","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ajhg.2010.05.017","volume":"87","author":"DL Duffy","year":"2010","unstructured":"Duffy, D. L. et al. IRF4 variants have age-specific effects on nevus count and predispose to melanoma. Am. J. Hum. Genet. 87, 6\u201316 (2010).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrclinonc201341_CR136","doi-asserted-by":"publisher","first-page":"e1002791","DOI":"10.1371\/journal.pgen.1002791","volume":"8","author":"S Li","year":"2012","unstructured":"Li, S. et al. GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. PLoS Genet. 8, e1002791 (2012).","journal-title":"PLoS Genet."},{"key":"BFnrclinonc201341_CR137","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","volume":"13","author":"C de Martel","year":"2012","unstructured":"de Martel, C. et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 13, 607\u2013615 (2012).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201341_CR138","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1200\/JCO.2012.41.8681","volume":"30","author":"ME Wood","year":"2012","unstructured":"Wood, M. E. et al. Second malignant neoplasms: assessment and strategies for risk reduction. J. Clin. Oncol. 30, 3734\u20133745 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR139","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1055-9965.EPI-11-0659","volume":"20","author":"S Bhatia","year":"2011","unstructured":"Bhatia, S. Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors. Cancer Epidemiol. Biomarkers Prev. 20, 2048\u20132067 (2011).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"BFnrclinonc201341_CR140","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1182\/blood-2004-06-2161","volume":"104","author":"JM Allan","year":"2004","unstructured":"Allan, J. M. et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 104, 3872\u20133877 (2004).","journal-title":"Blood"},{"key":"BFnrclinonc201341_CR141","doi-asserted-by":"publisher","first-page":"5221","DOI":"10.1182\/blood-2012-02-411215","volume":"119","author":"JC Hernandez-Boluda","year":"2012","unstructured":"Hernandez-Boluda, J. C. et al. A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera. Blood 119, 5221\u20135228 (2012).","journal-title":"Blood"},{"key":"BFnrclinonc201341_CR142","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nm.2407","volume":"17","author":"T Best","year":"2011","unstructured":"Best, T. et al. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat. Med. 17, 941\u2013943 (2011).","journal-title":"Nat. Med."},{"key":"BFnrclinonc201341_CR143","doi-asserted-by":"publisher","first-page":"580","DOI":"10.14219\/jada.archive.1968.0275","volume":"77","author":"SG Castigliano","year":"1968","unstructured":"Castigliano, S. G. Influence of continued smoking on the incidence of second primary cancers involving mouth, pharynx, and larynx. J. Am. Dent. Assoc. 77, 580\u2013585 (1968).","journal-title":"J. Am. Dent. Assoc."},{"key":"BFnrclinonc201341_CR144","doi-asserted-by":"publisher","first-page":"b5569","DOI":"10.1136\/bmj.b5569","volume":"340","author":"A Parsons","year":"2010","unstructured":"Parsons, A., Daley, A., Begh, R. & Aveyard, P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 340, b5569 (2010).","journal-title":"BMJ"},{"key":"BFnrclinonc201341_CR145","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/hed.20272","volume":"27","author":"K Lin","year":"2005","unstructured":"Lin, K. et al. Second primary malignancy of the aerodigestive tract in patients treated for cancer of the oral cavity and larynx. Head Neck 27, 1042\u20131048 (2005).","journal-title":"Head Neck"},{"key":"BFnrclinonc201341_CR146","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1023\/A:1023060315781","volume":"14","author":"KA Do","year":"2003","unstructured":"Do, K. A. et al. Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control 14, 131\u2013138 (2003).","journal-title":"Cancer Causes Control"},{"key":"BFnrclinonc201341_CR147","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1200\/JCO.2011.38.4099","volume":"30","author":"ML Gillison","year":"2012","unstructured":"Gillison, M. L. et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J. Clin. Oncol. 30, 2102\u20132111 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR148","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10552-008-9277-8","volume":"20","author":"X Leon","year":"2009","unstructured":"Leon, X. et al. Influence of the persistence of tobacco and alcohol use in the appearance of second neoplasm in patients with a head and neck cancer. A case-control study. Cancer Causes Control 20, 645\u2013652 (2009).","journal-title":"Cancer Causes Control"},{"key":"BFnrclinonc201341_CR149","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/aje\/kwn422","volume":"169","author":"JA Knight","year":"2009","unstructured":"Knight, J. A. et al. Alcohol intake and cigarette smoking and risk of a contralateral breast cancer: the women's environmental cancer and radiation epidemiology study. Am. J. Epidemiol. 169, 962\u2013968 (2009).","journal-title":"Am. J. Epidemiol."},{"key":"BFnrclinonc201341_CR150","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1200\/JCO.2009.23.1597","volume":"27","author":"CI Li","year":"2009","unstructured":"Li, C. I., Daling, J. R., Porter, P. L., Tang, M. T. & Malone, K. E. Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. J. Clin. Oncol. 27, 5312\u20135318 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR151","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10549-006-9446-y","volume":"105","author":"A Trentham-Dietz","year":"2007","unstructured":"Trentham-Dietz, A., Newcomb, P. A., Nichols, H. B. & Hampton, J. M. Breast cancer risk factors and second primary malignancies among women with breast cancer. Breast Cancer Res. Treat. 105, 195\u2013207 (2007).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrclinonc201341_CR152","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/oxfordjournals.aje.a009349","volume":"146","author":"F Levi","year":"1997","unstructured":"Levi, F., Randimbison, L., La Vecchia, C., Erler, G. & Te, V. C. Incidence of invasive cancers following squamous cell skin cancer. Am. J. Epidemiol. 146, 734\u2013739 (1997).","journal-title":"Am. J. Epidemiol."},{"key":"BFnrclinonc201341_CR153","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/archderm.142.4.433","volume":"142","author":"L Titus-Ernstoff","year":"2006","unstructured":"Titus-Ernstoff, L. et al. Multiple primary melanoma: two-year results from a population-based study. Arch. Dermatol. 142, 433\u2013438 (2006).","journal-title":"Arch. Dermatol."},{"key":"BFnrclinonc201341_CR154","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0190-9622(96)90041-9","volume":"34","author":"DS Rigel","year":"1996","unstructured":"Rigel, D. S., Friedman, R. J. & Kopf, A. W. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J. Am. Acad. Dermatol. 34, 839\u2013847 (1996).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrclinonc201341_CR155","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s10549-010-1153-z","volume":"126","author":"B Majed","year":"2011","unstructured":"Majed, B., Dozol, A., Ribassin-Majed. L., Senouci, K. & Asselain, B. Increased risk of contralateral breast cancers among overweight and obese women: a time-dependent association. Breast Cancer Res. Treat. 126, 729\u2013738 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrclinonc201341_CR156","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/CEJ.0b013e3282f75ee5","volume":"17","author":"L Sanchez","year":"2008","unstructured":"Sanchez, L. et al. Risk factors for second primary tumours in breast cancer survivors. Eur. J. Cancer Prev. 17, 406\u2013413 (2008).","journal-title":"Eur. J. Cancer Prev."},{"key":"BFnrclinonc201341_CR157","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3322\/caac.21142","volume":"62","author":"CL Rock","year":"2012","unstructured":"Rock, C. L. et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J. Clin. 62, 243\u2013274 (2012).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrclinonc201341_CR158","first-page":"1457","volume":"61","author":"ST Mayne","year":"2001","unstructured":"Mayne, S. T. et al. Randomized trial of supplemental beta-carotene to prevent second head and neck cancer. Cancer Res. 61, 1457\u20131463 (2001).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201341_CR159","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1002\/ijc.22042","volume":"119","author":"I Bairati","year":"2006","unstructured":"Bairati, I. et al. Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients. Int. J. Cancer 119, 2221\u20132224 (2006).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201341_CR160","unstructured":"World Cancer Research Fund\/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective [online] , (2007)."},{"key":"BFnrclinonc201341_CR161","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3322\/caac.20096","volume":"61","author":"RA Smith","year":"2011","unstructured":"Smith, R. A. et al. Cancer screening in the United States, a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J. Clin. 61, 8\u201330 (2011).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrclinonc201341_CR162","volume-title":"From Cancer Patient to Cancer Survivor, Lost in Transition: An American Society of Clinical Oncology and Institute of Medicine Symposium","author":"M Hewitt","year":"2006","unstructured":"Hewitt, M. & Ganz, P. A. (Eds) From Cancer Patient to Cancer Survivor, Lost in Transition: An American Society of Clinical Oncology and Institute of Medicine Symposium (The National Academies Press, 2006)."},{"key":"BFnrclinonc201341_CR163","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3322\/canjclin.57.2.75","volume":"57","author":"D Saslow","year":"2007","unstructured":"Saslow, D. et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J. Clin. 57, 75\u201389 (2007).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrclinonc201341_CR164","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.2009.27.0835","volume":"29","author":"E Warner","year":"2011","unstructured":"Warner, E. et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J. Clin. Oncol. 29, 1664\u20131669 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR165","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687\u20131717 (2005).","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"BFnrclinonc201341_CR166","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(05)74803-0","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell, A. et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60\u201362 (2005).","journal-title":"Lancet"},{"key":"BFnrclinonc201341_CR167","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","volume":"25","author":"AS Coates","year":"2007","unstructured":"Coates, A. S. et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1\u201398 J. Clin. Oncol. 25, 486\u2013492 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR168","unstructured":"BIG 1\u201398 Collaborative Group. et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N. Engl. J. Med. 361, 766\u2013776 (2009)."},{"key":"BFnrclinonc201341_CR169","doi-asserted-by":"crossref","unstructured":"Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9, 45\u201353 (2008).","DOI":"10.1016\/S1470-2045(07)70385-6"},{"key":"BFnrclinonc201341_CR170","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/jnci\/djk049","volume":"99","author":"J Cuzick","year":"2007","unstructured":"Cuzick, J. et al. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J. Natl Cancer Inst. 99, 272\u2013282 (2007).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR171","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","volume":"364","author":"PE Goss","year":"2011","unstructured":"Goss, P. E. et al. Exemestane for breast-cancer prevention in postmenopausal women. N. Engl. J. Med. 364, 2381\u20132391 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201341_CR172","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"B Fisher","year":"2005","unstructured":"Fisher, B. et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst. 97, 1652\u20131662 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR173","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel, V. G. et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295, 2727\u20132741 (2006).","journal-title":"JAMA"},{"key":"BFnrclinonc201341_CR174","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1470-2045(11)70030-4","volume":"12","author":"J Cuzick","year":"2011","unstructured":"Cuzick, J. et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 12, 496\u2013503 (2011).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201341_CR175","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1001\/jama.298.3.289","volume":"298","author":"JP Pierce","year":"2007","unstructured":"Pierce, J. P. et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 298, 289\u2013298 (2007).","journal-title":"JAMA"},{"key":"BFnrclinonc201341_CR176","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/jnci\/djj494","volume":"98","author":"RT Chlebowski","year":"2006","unstructured":"Chlebowski, R. T. et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J. Natl Cancer Inst. 98, 1767\u20131776 (2006).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR177","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1016\/j.ejca.2010.07.028","volume":"46","author":"CM Friedenreich","year":"2010","unstructured":"Friedenreich, C. M., Neilson, H. K. & Lynch, B. M. State of the epidemiological evidence on physical activity and cancer prevention. Eur. J. Cancer 46, 2593\u20132604 (2010).","journal-title":"Eur. J. Cancer"},{"key":"BFnrclinonc201341_CR178","doi-asserted-by":"publisher","first-page":"900","DOI":"10.7326\/0003-4819-157-11-201212040-00539","volume":"18","author":"VA Moyer","year":"2012","unstructured":"Moyer, V. A. & U.S. Preventive Services Task Force. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann. Intern. Med. 18, 900\u2013904 (2012).","journal-title":"Ann. Intern. Med."},{"key":"BFnrclinonc201341_CR179","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jama.1997.03540350065035","volume":"277","author":"W Burke","year":"1997","unstructured":"Burke, W. et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 277, 915\u2013919 (1997).","journal-title":"JAMA"},{"key":"BFnrclinonc201341_CR180","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1001\/jama.1997.03540360065034","volume":"277","author":"W Burke","year":"1997","unstructured":"Burke, W. et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277, 997\u20131003 (1997).","journal-title":"JAMA"},{"key":"BFnrclinonc201341_CR181","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1001\/jama.296.12.1507","volume":"296","author":"NM Lindor","year":"2006","unstructured":"Lindor, N. M. et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296, 1507\u20131517 (2006).","journal-title":"JAMA"},{"key":"BFnrclinonc201341_CR182","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.bpobgyn.2005.10.017","volume":"20","author":"A Rosenthal","year":"2006","unstructured":"Rosenthal, A. & Jacobs, I. Familial ovarian cancer screening. Best Pract. Res. Clin. Obstet. Gynaecol. 20, 321\u2013338 (2006).","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"BFnrclinonc201341_CR183","doi-asserted-by":"crossref","unstructured":"Collaborative Group on Epidemiological Studies of Ovarian Cancer et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371, 303\u2013314 (2008).","DOI":"10.1016\/S0140-6736(08)60167-1"},{"key":"BFnrclinonc201341_CR184","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bpobgyn.2009.08.010","volume":"24","author":"GF Grimbizis","year":"2010","unstructured":"Grimbizis, G. F. & Tarlatzis, B. C. The use of hormonal contraception and its protective role against endometrial and ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 24, 29\u201338 (2010).","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"BFnrclinonc201341_CR185","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/bmj.39289.649410.55","volume":"335","author":"PC Hannaford","year":"2007","unstructured":"Hannaford, P. C. et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 335, 651 (2007).","journal-title":"BMJ"},{"key":"BFnrclinonc201341_CR186","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/jmg.2003.010918","volume":"41","author":"H Hampel","year":"2004","unstructured":"Hampel, H., Sweet, K., Westman, J. A., Offit, K. & Eng, C. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J. Med. Genet. 41, 81\u201391 (2004).","journal-title":"J. Med. Genet."},{"key":"BFnrclinonc201341_CR187","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1080\/003655299750026443","volume":"34","author":"E Thiis-Evensen","year":"1999","unstructured":"Thiis-Evensen, E. et al. Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study, I. Scand. J. Gastroenterol. 34, 414\u2013420 (1999).","journal-title":"Scand. J. Gastroenterol."},{"key":"BFnrclinonc201341_CR188","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","volume":"376","author":"PM Rothwell","year":"2010","unstructured":"Rothwell, P. M. et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376, 1741\u20131750 (2010).","journal-title":"Lancet"},{"key":"BFnrclinonc201341_CR189","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1158\/1940-6207.CAPR-11-0391","volume":"5","author":"AT Chan","year":"2012","unstructured":"Chan, A. T. et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev. Res. (Phila) 5, 164\u2013178 (2012).","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"BFnrclinonc201341_CR190","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1600-0609.2005.00458.x","volume":"66","author":"P Mauch","year":"2005","unstructured":"Mauch, P. et al. Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9\u201316, Bellagio, Italy. Eur. J. Haematol. Suppl. 66, 68\u201376 (2005).","journal-title":"Eur. J. Haematol. Suppl."},{"key":"BFnrclinonc201341_CR191","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa1102873","volume":"365","author":"DR Aberle","year":"2011","unstructured":"Aberle, D. R. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395\u2013409 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201341_CR192","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1200\/JCO.2004.05.055","volume":"22","author":"A Liede","year":"2004","unstructured":"Liede, A., Karlan, B. Y. & Narod, S. A. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J. Clin. Oncol. 22, 735\u2013742 (2004).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR193","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3322\/caac.20066","volume":"60","author":"AM Wolf","year":"2010","unstructured":"Wolf, A. M. et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J. Clin. 60, 70\u201398 (2010).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrclinonc201341_CR194","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1470-2045(06)71010-5","volume":"8","author":"JN Bishop","year":"2007","unstructured":"Bishop, J. N., Harland, M., Randerson-Moor, J. & Bishop, D. T. Management of familial melanoma. Lancet Oncol. 8, 46\u201354 (2007).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201341_CR195","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/jnci\/88.1.17","volume":"88","author":"M Berwick","year":"1996","unstructured":"Berwick, M., Begg, C. B., Fine, J. A., Roush, G. C. & Barnhill, R. L. Screening for cutaneous melanoma by skin self-examination. J. Natl Cancer Inst. 88, 17\u201323 (1996).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR196","unstructured":"Travis, L. B. Outcomes in cancer survivors who develop second malignant neoplasms. J. Clin. Oncol. Podcast Archive [online] , (2013)."},{"key":"BFnrclinonc201341_CR197","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/jnci\/djs473","volume":"105","author":"JW Elena","year":"2013","unstructured":"Elena, J. W. et al. Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J. Natl Cancer Inst. 105, 85\u201394 (2013).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR198","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrg3352","volume":"14","author":"HE Wheeler","year":"2013","unstructured":"Wheeler, H. E., Maitland, M. L., Dolan, M. E., Cox, N. J. & Ratain, M. J. Cancer pharmacogenomics: strategies and challenges. Nat. Rev. Genet. 14, 23\u201334 (2013).","journal-title":"Nat. Rev. Genet."},{"key":"BFnrclinonc201341_CR199","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/jnci\/djq390","volume":"102","author":"AN Freedman","year":"2010","unstructured":"Freedman, A. N. et al. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J. Natl Cancer Inst. 102, 1698\u20131705 (2010).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR200","unstructured":"National Institutes of Health, National Cancer Institute, and the LIVESTRONG Young Adult Alliance. Closing the gap: research and cancer care imperatives for adolescents and young adults with cancer [online] , (2006)."},{"key":"BFnrclinonc201341_CR201","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/jnci\/djq216","volume":"102","author":"LB Travis","year":"2010","unstructured":"Travis, L. B. et al. Testicular cancer survivorship: research strategies and recommendations. J. Natl Cancer Inst. 102, 1114\u20131130 (2010).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR202","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1158\/0008-5472.CAN-12-1728","volume":"72","author":"G Choi","year":"2012","unstructured":"Choi, G. et al. Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms. Cancer Res. 72, 6425\u20136434 (2012).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201341_CR203","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/jnci\/dji128","volume":"97","author":"AN Freedman","year":"2005","unstructured":"Freedman, A. N. et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J. Natl Cancer Inst. 97, 715\u2013723 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201341_CR204","unstructured":"National Childhood Cancer Foundation. Cure Search for Children's Cancer [online] , (2013)."},{"key":"BFnrclinonc201341_CR205","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1200\/JCO.2012.43.4951","volume":"30","author":"W Landier","year":"2012","unstructured":"Landier, W. et al. Yield of screening for long-term complications using the children's oncology group long-term follow-up guidelines. J. Clin. Oncol. 30, 4401\u20134408 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR206","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1200\/JCO.2011.34.6585","volume":"29","author":"GT Armstrong","year":"2011","unstructured":"Armstrong, G. T. et al. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J. Clin. Oncol. 29, 3056\u20133064 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201341_CR207","doi-asserted-by":"publisher","first-page":"5088","DOI":"10.1200\/JCO.2010.29.5683","volume":"28","author":"MT Milano","year":"2010","unstructured":"Milano, M. T., Li, H., Gail, M. H., Constine, L. S. & Travis, L. B. Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study. J. Clin. Oncol. 28, 5088\u20135096 (2010).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2013.41.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2013.41","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2013.41.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:24:06Z","timestamp":1684466646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2013.41"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,26]]},"references-count":207,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["BFnrclinonc201341"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2013.41","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,26]]}}}